Somerset Emsam "not approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's March 27 "not approvable" letter for Somerset Pharmaceuticals' Emsam (selegiline transdermal system) requests additional efficacy data for the depression patch. Somerset will meet with FDA "to review and clarify their comments," the firm say